Axonics Inc. drops as much as 5.4%, the most intraday since May 2, after the medical technology company announced that Chief Financial Officer
- Says
Kari Keese , vice president of finance and accounting, will succeed Dearen on Oct. 2 - Keese joined the company in 2014; prior to AXNX, she was controller at Vessix Vascular, Inc., a company led by AXNX CEO Raymond Cohen and Dearen that was acquired by Boston Scientific in late 2012
- AXNX also reaffirms fiscal year 2023 revenue guidance of $358 million
- “Changes at the CFO level always have the potential to ...